medigraphic.com
Instituto Nacional de Salud Pública

2021, Número 6

<< Anterior Siguiente >>

salud publica mex 2021; 63 (6)


Tendencia en la prevalencia de síndrome metabólico y sus componentes en adultos mexicanos, 2006-2018

Rojas-Martínez R, Aguilar-Salinas CA, Romero-Martínez M, Castro-Porras L, Gómez-Velasco D, Mehta R

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 713-724
Archivo PDF: 325.76 Kb.


RESUMEN

Objetivo. Examinar las tendencias en la prevalencia del síndrome metabólico (SM) y de sus componentes. Material y métodos. Se analizaron datos de 27 800 adultos mexicanos que participaron en las Ensanut 2006, 2012, 2016 y 2018. Se utilizó regresión lineal en cada periodo de Ensanut para evaluar las tendencias lineales temporales en la prevalencia del SM. Se obtuvieron modelos de regresión logística para calcular el cambio porcentual, P para la tendencia y las asociaciones entre la SM con el riesgo de desarrollar en 10 años diabetes mellitus tipo 2 utilizando la Finnish Diabetes Risk Score (FINDRISC) y enfermedad cardiovascular utilizando Globorisk. Resultados. La prevalencia de SM en adultos mexicanos según la definición armonizada fue: 40.2, 57.3, 59.99 y 56.31%, en 2006, 2012, 2016 y 2018 respectivamente (p para tendencia ‹0.0001). En 2018, 7.62% de los casos de síndrome metabólico tenían un riesgo significativo de DM2 incidente y 11.6% de ECV. Conclusión. Se estima que los adultos mexicanos con síndrome metabólico son 36.5 millones; de ellos, dos millones tienen un alto riesgo de desarrollar DMT2 en los próximos 10 años y 2.5 millones enfermedades cardiovasculares.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769-78. https://doi.org/10.2337/ diacare.28.7.1769

  2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. https://doi.org/10.1161/ CIRCULATIONAHA.105.169404

  3. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care. 2003;26(11):3153-9. https://doi.org/10.2337/diacare.26.11.3153

  4. Marott S, Nordestgaard BG, Tybjærg-Hansen A, Benn M. Components of the metabolic syndrome and risk of Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101(8):3212-21. https://doi.org/10.1210/jc.2015-3777

  5. Scuteri A, Najjar SS, Morrell CH, Lakatta EG. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events. Diabetes Care. 2005;28(4):882-7. https://doi.org/10.2337/diacare.28.4.882

  6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709-16. https://doi.org/10.1001/jama.288.21.2709

  7. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust. 2006;185(8):445-9 https://doi.org/10.5694/j.1326-5377.2006. tb00644.x

  8. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-36. https://doi.org/10.1161/ATVBAHA.107.151092

  9. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745-9 https://doi.org/10.2337/diacare.28.11.2745

  10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-9. https://doi.org/10.1001/ jama.287.3.356

  11. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA. 2001;285(19):2486- 97. https://doi.org/10.1001/jama.285.19.2486

  12. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059-62. https://doi.org/10.1016/S0140- 6736(05)67402-8

  13. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, Shama-Levy T, Rauda J, Ávila-Burgos L, et al. Metabolic syndrome in Mexican adults. Results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52(suppl 1):S11-S18. https://doi.org/10.1590/s0036- 36342010000700004

  14. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822. https://doi.org/10.1210/er.2008-0024

  15. Shin D, Kongpakpaisarn K, Bohra C. Trends in the prevalence of metabolic syndrome and its components in the United States 2007-2014. Int J Cardiol. 2018;259:216-19. https://doi.org/10.1016/j.ijcard.2018.01.139

  16. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011;34(1):216-9. https://doi.org/10.2337/dc10-0879

  17. Palmer MK, Toth PP. Trends in lipids, obesity, metabolic syndrome, and Diabetes Mellitus in the United States: An NHANES Analysis (2003-2004 to 2013-2014). Obesity (Silver Spring). 2019;27(2):309-14. https://doi. org/10.1002/oby.22370

  18. NCD Risk Factor Collaboration (NCD-RisC)—Americas Working Group. Trends in cardiometabolic risk factors in the Americas between 1980 and 2014: a pooled analysis of population-based surveys. Lancet Glob Health. 2020;8(1):e123-e133. https://doi.org/10.1016/S2214- 109X(19)30484-X

  19. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. https://doi.org/10.1161/CIRCULATIONAHA. 109.192644

  20. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Avila M, Sepúlveda-Amor J. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca: Instituto Nacional de Salud Pública, 2006.

  21. Romero-Martínez M, Shamah-Levy T, Franco-Núñez A, Villalpando S, Cuevas-Nasu L, Gutiérrez JP, et al. Encuesta Nacional de Salud y Nutrición 2012: diseño y cobertura. Salud Publica Mex. 2013;55(supl 2):S332-S340. https://doi.org/10.21149/spm.v55s2.5132

  22. Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, Méndez Gómez-Humarán I, Gaona-Pineda EB, Gómez-Acosta LM, et al. Diseño metodológico de la Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Salud Publica Mex. 2017;59(3):299-305. http://doi. org/10.21149/8593

  23. Romero-Martínez M, Shamah-Levy T, Vielma-Orozco E, Heredia- Hernández O, Mojica-Cuevas J, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2018-19: metodología y perspectivas. Salud Publica Mex. 2019;61(6):917-23. https://doi.org/10.21149/11095

  24. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. https://doi.org/10.1001/jama.2013.284427

  25. The IPAQ group. 2005. International Physical Activity Questionnaire IPAQ [cited April, 2021]. Available from: https://sites.google.com/site/ theipaq/home

  26. World Health Organization. Recomendaciones mundiales sobre la actividad física para la salud. Geneva: WHO, 2010 [cited April, 2021]. Available from: http://whqlibdoc.who.int/publications/2010/9789243599977_ spa.pdf

  27. Lindström J, Tuomilehto J. The Diabetes Risk Score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-31. https://doi. org/10.2337/diacare.26.3.725

  28. Instituto Mexicano del Seguro Social. Guía de Práctica Clínica Diagnóstico y tratamiento de dislipidemias (hipercolesterolemia) en el adulto. Actualización 2016. Mexico: Instituto Mexicano del Seguro Social, 2016 [cited April, 2021]. Available from: http://www.imss.gob.mx/sites/all/statics/ guiasclinicas/233GER.pdf

  29. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-Salinas CA, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017;5(3):196-213. https://doi.org/10.1016/S2213-8587(17)30015-3

  30. World Health Organization. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series: No.31. WHO, 2001 [cited April, 2021]. Available from: https://www.who.int/healthinfo/paper31.pdf

  31. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644-50. https://doi.org/10.1001/archinte.165.22.2644




2020     |     www.medigraphic.com